Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
2.600
+0.160 (6.56%)
At close: Aug 13, 2025, 4:00 PM
2.620
+0.020 (0.77%)
After-hours: Aug 13, 2025, 4:58 PM EDT
Annexon Employees
Annexon had 100 employees as of December 31, 2024. The number of employees increased by 29 or 40.85% compared to the previous year.
Employees
100
Change (1Y)
29
Growth (1Y)
40.85%
Revenue / Employee
n/a
Profits / Employee
-$1,673,800
Market Cap
285.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ANNX News
- 6 days ago - Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - GlobeNewsWire
- 20 days ago - Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - GlobeNewsWire
- 4 weeks ago - Annexon: Lead GBS Therapy Stokes Near-Term Potential - Seeking Alpha
- 2 months ago - Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewsWire
- 2 months ago - Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - GlobeNewsWire
- 3 months ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewsWire